Evidence map›Paper›PMID 37436522›Full record

ArticleEuropean journal of pediatrics2023

Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.

Rodrigo Velarde-Salcedo, Luis Fernando Pérez-González, Ana Socorro Rodríguez-Báez, Francisco Javier Arriaga-García, Rosa Del Carmen Milán-Segovia, Silvia Romano-Moreno, Susanna Edith Medellín-Garibay

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rodrigo Velarde-SalcedoFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México.
Luis Fernando Pérez-GonzálezHospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, S.L.P., México.
Ana Socorro Rodríguez-BáezFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México.
Francisco Javier Arriaga-GarcíaHospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, S.L.P., México.
Rosa Del Carmen Milán-SegoviaFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México.ORCID http://orcid.org/0000-0003-1040-8184
Silvia Romano-MorenoFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México.ORCID http://orcid.org/0000-0002-4885-3745
Susanna Edith Medellín-GaribayFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, S.L.P., México. susanna.medellin@uaslp.mx.ORCID http://orcid.org/0000-0002-3962-8474
Autonomous University of San Luis Potosí · MXHospital Central Dr. Ignacio Morones Prieto · MX

Funding

Consejo Nacional de Ciencia y Tecnología 782280Secretaría de Educación Pública 511-6/2020-8585
6 · The paper itself

Abstract

Antibiotics are among the most utilized drugs in pediatrics. Nonetheless, there is a lack in pharmacokinetics information for this population, and dosing criteria may vary between healthcare centers. Physiological variability associated with maturation in pediatrics makes it challenging to reach a consensus on adequate dosing, which is further accentuated in more vulnerable groups, such as critically ill or oncology patients. Model-informed precision dosing is a useful practice that allows dose optimization and attainment of antibiotic-specific pharmacokinetic/pharmacodynamic targets. The aim of this study was to evaluate the needs of model-informed precision dosing of antibiotics in a pediatrics unit, at a pilot scale. Pediatric patients under antibiotic treatment were monitored with either a pharmacokinetic/pharmacodynamic optimized sampling scheme or through opportunistic sampling. Clindamycin, fluconazole, linezolid, meropenem, metronidazole, piperacillin, and vancomycin plasma concentrations were quantified through a liquid chromatography coupled to mass spectrometry method. Pharmacokinetic parameters were estimated using a Bayesian approach to verify pharmacokinetic/pharmacodynamic target attainment. A total of 23 pediatric patients aged 2 to 16 years were included, and 43 dosing regimens were evaluated; 27 (63%) of them required adjustments as follows: 14 patients were underdosed, 4 were overdosed, and 9 patients needed infusion rate adjustments. Infusion rate adjustments were mostly recommended for piperacillin and meropenem; daily doses were augmented for vancomycin and metronidazole, meanwhile linezolid was adjusted for under- and overdosing. Clindamycin and fluconazole regimens were not adjusted at all.  Conclusion: Results showcase a lack of antibiotic pharmacokinetic/pharmacodynamic target attainment (particularly for linezolid, vancomycin, meropenem, and piperacillin), and the need for model-informed precision dosing in pediatrics. This study provides pharmacokinetic evidence which can further improve antibiotic dosing practices. What is Known: • Model-informed precision dosing is performed in pediatrics to optimize the treatment of antimicrobial drugs such as vancomycin and aminoglycosides, while its usefulness is debated for other groups (beta-lactams, macrolides, etc.). What is New: • Vulnerable pediatric subpopulations, such as critically ill or oncology patients, can benefit the most from model-informed precision dosing of antibiotics. • Model-informed precision dosing of linezolid, meropenem, piperacillin, and vancomycin is particularly useful in pediatrics, and further research may improve dosing practices altogether.

Indexed as

NeoplasmsVancomycinAnti-Bacterial AgentsBayes TheoremChildClindamycinCritical IllnessFluconazoleHumansLinezolidMeropenemMetronidazolePiperacillinAnti-Bacterial AgentsClindamycinFluconazoleLinezolidMeropenemMetronidazolePiperacillinVancomycinAntibioticsLiquid chromatography coupled to tandem mass spectrometry (LC-MS/MS)Model-informed precision dosing (MIPD)PediatricsPharmacokinetic/pharmacodynamic (PK/PD) targets

Identifiers

PMID37436522
OpenAlexW4383998152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.